Our method deploys novel peanut-specific human IgE monoclonal antibodies to enable reproducible in vitro models of the effector phase in food allergy as a first step in the effort to unveil new therapeutic targets to prevent mast cell activation in IgE-mediated allergy. This evidence concerns the gene IGHE and allergic disease.